Galmed Pharmaceuticals Ltd.
GLMD
$0.52
$0.0511.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.24% | -4.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.20% | -0.66% | |||
| Operating Income | -45.20% | 0.66% | |||
| Income Before Tax | -154.65% | 24.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -154.65% | 24.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -154.65% | 24.17% | |||
| EBIT | -45.20% | 0.66% | |||
| EBITDA | -45.65% | 0.67% | |||
| EPS Basic | -131.17% | 45.17% | |||
| Normalized Basic EPS | -33.98% | 30.51% | |||
| EPS Diluted | -131.17% | 45.17% | |||
| Normalized Diluted EPS | -33.98% | 30.51% | |||
| Average Basic Shares Outstanding | 10.16% | 38.30% | |||
| Average Diluted Shares Outstanding | 10.16% | 38.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||